Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from PBMs. The organizations are frequently erecting limitations to reimbursement, including significant price requirements and prior authorization that hinder user availability. In… Read More